Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +30

Gilead Sciences stock slips as earnings estimates shift

Analyst upgrade Dividend Earnings report AI-generated analysis

πŸ“ˆ Gilead Sciences reported quarterly revenue of USD 7.80 billion, a 10.6 percent year-over-year increase that beat analyst estimates by USD 400 million.

πŸ’° The company posted EPS of negative USD 6.75, surpassing the consensus estimate of negative USD 7.25 by USD 0.50.

πŸ’΅ Gilead declared a quarterly dividend of USD 0.82 per share, equivalent to USD 3.28 on an annualized basis.

πŸ“‰ The stock closed at USD 149.56, down 0.7 percent from the prior close and trading below its 52-week high of USD 157.29.

🏦 Erste Group Bank raised its fiscal 2026 EPS estimate to negative USD 0.44, positioning its forecast above the consensus of negative USD 0.48.

🎯 Analysts maintain a Moderate Buy consensus with an average price target of USD 158.78, roughly USD 9.22 higher than the current share price.

πŸ“… The next earnings report for Gilead is scheduled to be released on October 22, 2026.

πŸ’Ό As of September 22, 2026, Gilead Sciences had a market capitalization of USD 186.69 billion within the Health Care sector.

Bullish Signals
  • Gilead Sciences beat quarterly revenue estimates by USD 400 million, reporting USD 7.80 billion in sales compared to the consensus of USD 7.40 billion.
  • The company delivered EPS of negative USD 6.75, which was USD 0.50 better than the analyst consensus estimate of negative USD 7.25.
  • Gilead declared a quarterly dividend of USD 0.82 per share, providing an annualized yield equivalent to USD 3.28 per share.
  • Erste Group Bank raised its fiscal 2026 EPS forecast for Gilead to negative USD 0.44, indicating confidence in the company's financial trajectory.
Risk Factors
  • Despite strong revenue growth, Gilead Sciences stock closed down 0.7 percent and remained 4.9 percent below its 52-week high of USD 157.29.
Full Analysis
Gilead Sciences reported quarterly revenue of USD 7.80 billion for the period ending in September 2026, representing a 10.6 percent year-over-year increase. This sales figure significantly exceeded analyst consensus estimates by USD 400 million, with the company closing at USD 149.56 on the Nasdaq. Despite the strong top-line performance and a share price that remained below its 52-week high of USD 157.29, the stock experienced a slight decline of 0.7 percent from the prior session. The company posted earnings per share (EPS) of negative USD 6.75, which was better than the consensus estimate of negative USD 7.25, resulting in a positive variance of USD 0.50. Gilead also declared a quarterly dividend of USD 0.82 per share, annualizing to USD 3.28. Erste Group Bank revised its fiscal 2026 EPS forecast upward to negative USD 0.44 from negative USD 0.45, placing its projection slightly above the broader market consensus. Analyst sentiment remains cautiously optimistic with a Moderate Buy consensus rating and an average price target of USD 158.78, which sits approximately USD 9.22 above the current closing price. The market capitalization stood at USD 186.69 billion as of September 22, 2026. Investors are now awaiting the next earnings report scheduled for October 22, 2026, to assess continued growth momentum.